Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Buy” by Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have been assigned a consensus recommendation of “Buy” from the nineteen analysts that are presently covering the company, Marketbeat.com reports. Nineteen investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $48.21.

GH has been the topic of a number of recent analyst reports. Raymond James reaffirmed an “outperform” rating and set a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Guggenheim reaffirmed a “buy” rating and set a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Piper Sandler increased their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Barclays assumed coverage on Guardant Health in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price for the company.

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 2,768 shares of company stock valued at $98,798 over the last three months. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Guardant Health

A number of institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC raised its stake in shares of Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after purchasing an additional 230 shares in the last quarter. Summit Investment Advisors Inc. raised its position in Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock valued at $377,000 after acquiring an additional 391 shares in the last quarter. Arizona State Retirement System raised its position in Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock valued at $1,089,000 after acquiring an additional 403 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock valued at $102,000 after acquiring an additional 796 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its position in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $42.55 on Friday. Guardant Health has a 12 month low of $15.81 and a 12 month high of $50.89. The stock has a fifty day moving average price of $40.87 and a 200 day moving average price of $31.89. The company has a market cap of $5.25 billion, a P/E ratio of -11.95 and a beta of 1.32.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, research analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.